Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04825834 · ClinicalTrials.gov registry record
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
A clinical trial, sponsored by Delfi Diagnostics.
- Completed
- Registry status
- 2,992
- Enrollment target
NCT04825834: Completed study, sponsored by Delfi Diagnostics.
NCT04825834 is a clinical trial that has completed, run by Delfi Diagnostics. The registered enrollment target is 2,992 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04825834 has completed, sponsored by Delfi Diagnostics.
- COMPLETED
- Registry status
- 2,992 participants
- Enrollment target
Study Summary
The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
Interventions
- OTHER Blood Sample Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,992 participants |
| Start Date | 2021-03-22 |
| Est. Completion | 2025-07-15 |
What the finished NCT04825834 record still lists
NCT04825834 is an observational study that tracks outcomes without assigning an intervention. Its 2,992 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Blood Sample Collection is the first listed.
NCT04825834 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04825834 about?
NCT04825834 is a clinical study titled "DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)". The primary objective of this study, DELFI-L101, is to train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features.
What is the current status of trial NCT04825834?
This trial is currently completed. The enrollment target is 2,992 participants. The study started on 2021-03-22. Estimated completion is 2025-07-15.
What interventions are being tested in trial NCT04825834?
The interventions under investigation include: Blood Sample Collection (OTHER).
Who is sponsoring clinical trial NCT04825834?
This trial is sponsored by Delfi Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05297734 · 2,996 participants · NA
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- NCT03860883 · 2,998 participants · NA
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI